Leal Therapeutics

Biotech · Private

Novel therapeutics targeting central nervous system disorders

lealtx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
0 granted · 40 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2074Key Health Institute of Edmond, LLC—$100K
2075RGENIX, INC.——
2076Outpost Intros Inc.—$475K
2077Leal Therapeutics——
2078PHOENIX PHARMALABS, INC.—$3.5M
2079STEMCELLLIFE LLC——
2080Synergyan, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Press

1 article · matched on company name

Patents

USPTO · 0 granted of 40
  • Use Of Small Molecule Glutaminase Inhibitors For Treating Age-related Disordersapplication
  • Small Molecule Inhibitors Of Glutaminaseapplication
  • Compositions And Methods For Modulating GLS1application
  • Compositions And Methods For Modulating C3application
  • Use Of Small Molecule Glutaminase Inhibitors For Treating Age-related Disordersapplication
  • Use Of Small Molecule Glutaminase Inhibitors For Treating Age-related Disordersapplication
  • Use Of Small Molecule Glutaminase Inhibitors For Treating Age-related Disordersapplication
  • Compositions And Methods For Modulating SPTLC2application
  • Use Of Small Molecule Glutaminase Inhibitors For Treating Age-related Disordersapplication
  • Compositions And Methods For Modulating Apoeapplication
  • Small Molecule Inhibitors Of Glutaminaseapplication
  • Small Molecule Inhibitors Of Glutaminaseapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.